Palisade Bio Will Present PALI-2108 Data at UEG Week
The Denver-based company plans four presentations on its oral prodrug candidate from October 17 to October 20, 2026.
Updated on Sept. 28, 2026 in Healthcare
Live Poll
Will upcoming clinical trial results provide clearer evidence for the efficacy of new inflammatory disease treatments?
Palisade Bio will present new clinical data regarding its oral drug candidate PALI-2108 at the upcoming United European Gastroenterology Week. These sessions are scheduled to occur in Barcelona from October 17 to October 20, 2026.
Why it matters
The company aims to provide essential clinical and translational support to justify the continued development of PALI-2108. The data will help frame the drug's advancement into Phase 2 trials for ulcerative colitis and Crohn's disease.
Palisade Bio will deliver four total presentations, consisting of one oral briefing and three moderated poster sessions. This data release supports the company's efforts to move PALI-2108 from Phase 1b into Phase 2 development.
The players
Palisade Bio
This is a clinical-stage biopharmaceutical company headquartered in Denver that focuses on developing therapies for inflammatory and fibrotic diseases.
The details
The presentations will detail early clinical activity, pharmacokinetics, and safety findings for PALI-2108, which targets inflammatory and fibrotic diseases. Palisade Bio intends to leverage these findings to support the transition of the once-daily oral prodrug into broader Phase 2 studies.
Timeline
October 17 to October 20, 2026: United European Gastroenterology Week takes place in Barcelona.
October 18, 2026: The company will hold an oral presentation on Phase 1b results.
October 19, 2026: A poster presentation will focus on safety and tolerability.
October 20, 2026: Two poster presentations will cover clinical response and biomarkers.
Market Landscape
The transition to Phase 2 trials reflects the competitive pressure on clinical-stage biotechs to secure efficacy data for chronic digestive conditions. This move aligns Palisade Bio with industry trends of advancing targeted oral therapies to capture market share in the gastrointestinal space.
Investors and patients tracking treatment options for inflammatory bowel diseases can anticipate updates on drug safety and efficacy following these presentations. The data provided will influence the feasibility of future treatment availability for patients with Crohn's and ulcerative colitis.
The takeaway
Clinical data releases at major medical conferences remain a primary vehicle for biopharma companies to demonstrate proof-of-concept for pipeline assets. Readers should monitor these developments as key indicators for the viability of long-term medical innovation.
Further reading
Learn more about the latest innovations in the Healthcare sector.
More information
For more information, visit the Palisade Bio corporate information.
Live Poll
Will upcoming clinical trial results provide clearer evidence for the efficacy of new inflammatory disease treatments?
